Company profile

Glycemicon

A financing round worth more than CHF 3 million, and clinical trials on both humans and cats: things are progressing nicely at Glycemicon. The startup is working on making a substance that occurs naturally in humans and animals and which is suitable for use in treating diabetes.

More news about Glycemicon

02.07.2018 10:19

Glycemicon founder Nadja Mrosek named Female innovator of the year

Please login or
register to use the
awards follow feature
03.04.2018 17:05

Glycemicon completes Series A round with CHF 5 million

Please login or
register to use the
awards follow feature
19.04.2017 09:20

15 Swiss startups to present at Swiss Biotech Day

Please login or
register to use the
awards follow feature
09.02.2017 08:54

Glycemicon raises CHF3.25 million

Please login or
register to use the
awards follow feature
14.09.2016 21:17

Top 100 Swiss startups have been revealed

Please login or
register to use the
awards follow feature
24.03.2016 17:46

ETH Spark Award for a promising method for breast cancer detection

Please login or
register to use the
awards follow feature
10.02.2016 08:14

Almost a billion invested in Venture Kick startups

Please login or
register to use the
awards follow feature
Glycemicon

Founded
2013

Kanton
AG

Homepage

rss